CTEC vs. HIK, HCM, INDV, SN, AMS, TSTL, BVC, SPEC, CNSL, and GNS
Should you be buying ConvaTec Group stock or one of its competitors? The main competitors of ConvaTec Group include Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Smith & Nephew (SN), Advanced Medical Solutions Group (AMS), Tristel (TSTL), BATM Advanced Communications (BVC), INSPECS Group (SPEC), Cambridge Nutritional Sciences (CNSL), and Genus (GNS). These companies are all part of the "medical" sector.
Hikma Pharmaceuticals (LON:HIK) and ConvaTec Group (LON:CTEC) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.
Hikma Pharmaceuticals pays an annual dividend of GBX 57 per share and has a dividend yield of 2.9%. ConvaTec Group pays an annual dividend of GBX 5 per share and has a dividend yield of 2.0%. Hikma Pharmaceuticals pays out 8,382.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ConvaTec Group pays out 10,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Hikma Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.
Hikma Pharmaceuticals has higher revenue and earnings than ConvaTec Group. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than ConvaTec Group, indicating that it is currently the more affordable of the two stocks.
Hikma Pharmaceuticals received 446 more outperform votes than ConvaTec Group when rated by MarketBeat users. Likewise, 70.56% of users gave Hikma Pharmaceuticals an outperform vote while only 66.54% of users gave ConvaTec Group an outperform vote.
37.5% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.7% of ConvaTec Group shares are owned by institutional investors. 30.7% of Hikma Pharmaceuticals shares are owned by company insiders. Comparatively, 20.1% of ConvaTec Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Hikma Pharmaceuticals has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Comparatively, ConvaTec Group has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
Hikma Pharmaceuticals has a net margin of 6.61% compared to Hikma Pharmaceuticals' net margin of 6.08%. ConvaTec Group's return on equity of 8.81% beat Hikma Pharmaceuticals' return on equity.
Hikma Pharmaceuticals currently has a consensus target price of GBX 2,068.75, indicating a potential upside of 4.59%. ConvaTec Group has a consensus target price of GBX 307.17, indicating a potential upside of 20.65%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ConvaTec Group is more favorable than Hikma Pharmaceuticals.
In the previous week, ConvaTec Group had 1 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 2 mentions for ConvaTec Group and 1 mentions for Hikma Pharmaceuticals. ConvaTec Group's average media sentiment score of 0.90 beat Hikma Pharmaceuticals' score of -0.31 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.
Summary
Hikma Pharmaceuticals beats ConvaTec Group on 12 of the 20 factors compared between the two stocks.
Get ConvaTec Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTEC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ConvaTec Group Competitors List
Related Companies and Tools
